Corticosteroid Pulses for Hospitalized Patients with COVID‐19: Effects on Mortality
Authors:
- Ivan CusacovichICIvan Cusacovich
- Álvaro AparisiÁAÁlvaro Aparisi
- Miguel MarcosMMMiguel Marcos
- Cristina Ybarra-FalcónCYCristina Ybarra-Falcón
- Carolina Iglesias-EchevarriaCICarolina Iglesias-Echevarria
- Maria Lopez-VelosoMLMaria Lopez-Veloso
- Julio Barraza-VengoecheaJBJulio Barraza-Vengoechea
- Carlos DueñasCDCarlos Dueñas
- Santiago Antonio Juarros MartínezSMSantiago Antonio Juarros Martínez
- Beatriz Rodríguez-AlonsoBRBeatriz Rodríguez-Alonso
- José-Ángel Martín-OterinoJMJosé-Ángel Martín-Oterino
- Miguel Montero-BaladiaMMMiguel Montero-Baladia
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Abstract
Objectives. To assess the influence of corticosteroid pulses on 60‐day mortality in hospitalized patients with severe COVID‐19. Methods. We designed a multicenter retrospective cohort study in three teaching hospitals of Castilla y León, Spain (865,096 people). We selected patients with confirmed COVID‐19 and lung involvement with a pO2/FiO2Results. From 2933 patients, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses (250 mg of methylprednisolone for three days), and 133 were not. 30.3% (37/122) of patients died in the corticosteroid pulse group and 42.9% (57/133) in the nonexposed cohort. These differences (12.6%, 95% CI [8·54‐16.65]) were statically significant (log‐rank 4.72, p = 0, 03). We performed PSM using the exact method. Mortality differences remained in the PSM group (log‐rank 5.31, p = 0.021) and were still significant after a Cox regression model (HR for corticosteroid pulses 0.561; p = 0.039). Conclusions. This study provides evidence about treatment with corticosteroid pulses in severe COVID‐19 that might significantly reduce mortality. Strict inclusion and exclusion criteria with that selection process set a reliable frame to compare mortality in both the exposed and nonexposed groups.Keywords
All Related Versions
Funding Information
- Roche
This publication has 45 references indexed in Scilit:
- Lung Function and Organ Dysfunctions in 178 Patients Requiring Mechanical Ventilation During The 2009 Influenza A (H1N1) PandemicCritical Care, 2011
- Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumoniaJournal of Infection, 2011
- Genomic and nongenomic effects of glucocorticoidsNature Clinical Practice Rheumatology, 2008
- Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysisBMJ, 2008
- Endogenous glucocorticoids control neutrophil mobilization from bone marrow to blood and tissues in non‐inflammatory conditionsBritish Journal of Pharmacology, 2007
- Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptorsClinical Immunology, 2006
- Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro.Thorax, 1994
- High-Dose Corticosteroids in Patients with the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1987
- Early Methylprednisolone Treatment for Septic Syndrome and the Adult Respiratory Distress SyndromeChest, 1987
- Early Steroid Therapy for Respiratory FailureArchives of Surgery, 1985